Two-step epstein-barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma

Clinical and Vaccine Immunology

Volumn 16, Issue 5, 2009, Pages 706-711

  Paramita, Dewi K ^a   Fachiroh, Jajah ^a   Haryana, Sofia M ^a   Middeldorp, Jaap M ^b  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS CAPSID ANTIGEN; VIRUS CAPSID ANTIGEN P18; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER SCREENING; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; MALE; MASS SCREENING; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; YOUNG ADULT;

EID: 66849109421     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00425-08     Document Type: Article

References (27)

1. Chan, K. H., Y. L. Gu, F. Ng, P. S. Ng, W. H. Seto, J. S. Sham, D. Chua, W. Wei, Y. L. Chen, W. Luk, Y. S. Zong, and M. H. Ng. 2003. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int. J. Cancer 105:706-709.
2. Chien, Y. C., J. Y. Chen, M. Y. Liu, H. I. Yang, M. M. Hsu, J. Y. Chen, and C. S. Yang. 2001. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345:1877-1882.
3. Crowther, J. R. 2001. Validation of diagnostic test for infectious disease.Methods Mol. Biol. 149:301-346.
4. Dardari, R., W. Hinderer, D. Lang, A. Benider, B. El Gueddari, I. Joab, A.Benslimane, and M. Khyatti. 2001. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J. Clin.Microbiol. 39:3164-3170.
5. de Sanjose, S., R. Bosch, T. Schouten, S. A. Verkuijlen, A. Nieters, L. Foretova, M. Maynadie, P. L. Cocco, A. Staines, N. Becker, P. Brennan, Y.Benavente, P. Boffetta, C. J. Meijer, and J. M. Middeldorp. 2007. Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in large series of lymphoma subjects and matched controls. Int. J. Cancer 121:1806-1812.
6. de Vathaire, F., H. Sancho-Garnier, H. de The, C. Pieddeloup, G. Schwab, J. H. Ho, R. Ellousz, C. Michaeu, M. Cammoun, Y. Cachin, and G. de The.1988. Prognostic value of EBV markers in the clinical management of na- sopharyngeal carcinoma (NPC): a multicenter follow-up study. Int. J. Cancer 42:176-181.
7. Fachiroh, J., T. Schouten, B. Hariwiyanto, D. K. Paramita, A. Harijadi, S. M. Haryana, M. H. Ng, and J. M. Middeldorp. 2004. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.J. Infect. Dis. 190:53-62.
8. Fachiroh, J., D. K. Paramita, B. Hariwiyanto, A. Harijadi, H. L. Dahlia, S. R. Indrasari, H. Kusumo, Y. S. Zeng, T. Schouten, S. Mubarika, and J. M. Middeldorp. 2006. Single assay combination of Epstein-Barr virus (EBV) EBNA1 and viral capsid antigen p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: option for field screening. J. Clin. Mi-crobiol. 44:1459-1467.
9. Fachiroh, J., P. R. Prasetyanti, D. K. Paramita, A. T. Prasetyawati, D. W.Anggrahini, S. M. Haryana, and J. M. Middeldorp. 2008. Dried-blood sampling for Epstein-Barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. J. Clin. Microbiol. 46:1374-1380.
10. Gartner, B. C., J. M. Fischinger, K. Roemer, M. Mak, B. Fleurent, and N. Mueller-Lantzsch. 2001. Evaluationofrecombinantlineblotfordiagnosis of Epstein-Barr virus compared with ELISA, using immunofluorescence as reference method. J. Virol. Methods 93:89-96.
11. Gartner, B. C., R. D. Hess, D. Bandt, A. Kruse, A. Rethwilm, K. Roemer, and N. Mueller-Lantzsch. 2003. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin. Diagn. Lab. Immunol. 10:78-82.
12. Henle, W., G. Henle, H. C. Ho, P. Burtin, Y. Cachin, P. Clifford, A. De Schryver, G. de The, V. Diehl, and G. Klein. 1970. Antibodies to Epstein Barr virus in nasopharyngeal carcinoma, other head and neck neoplasm group, and control group. J. Int. Cancer Inst. 44:225-231.
13. Henle, G., and W. Henle. 1976. Epstein-Barr Virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 17:1-7.
14. Ho, H. C., M. H. Ng, H. C. Kwan, and J. C. Chau. 1976. Epstein-Barr virus specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br. J.Cancer 34:55-60.
15. Ji,M.F.,D.K.Wang,Y.L.Yu,Y.Q.Guo,J.S.Liang,W.M.Cheng,Y.S.Zong, K. H. Chan, S. P. Ng, W. I. Wei, D. T. T. Chua, J. S. T. Sham, and M. H. Ng.2007. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br. J. Cancer 96:623-630.
16. Karray, H., W. Ayadi, L. Fki, A. Hammami, J. Daoud, M. M. Drira, M. Frikha, R. Jlidi, and J. M. Middeldorp. 2005. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyn- geal carcinoma in two age groups from Tunisia. J. Med. Virol. 75:593-602.
17. Lin, J. C., J. S. Jan, C. Y. Hsu, W. M. Liang, R. S. Jiang, and W. Y. Wang.2003. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J. Clin. Oncol. 21:631-637.
18. Loh, K. S., B. C. Goh, J. Lu, W. S. Hsieh, and L. Tan. 2006. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch. Otolaryngol.Head Neck Surg. 132:82-85.
19. Middeldorp, J. M., and P. Herbrink. 1988. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J. Virol.Methods 21:133-146.
20. Ng, W. T., T. K. Yau, R. W. Yung, W. M. Sze, A. H. Tsang, A. L. Law, and A. W. Lee. 2005. Screening for family members of patients with nasopharyn- geal carcinoma. Int. J. Cancer 113:998-1001.
21. Ng, M. H., K. H. Chan, S. P. Ng, and Y. S. Zong. 2006. Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma.Chinese J. Cancer 25:250-256.
22. Paramita, D. K., J. Fachiroh, W. T. Artama, E. van Benthem, S. M. Haryana, and J. M. Middeldorp. 2007. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J. Med. Virol.79:1710-1721.
23. Stevens, S. J. C., S. A. W. M. Verkuijlen, B. Hariwiyanto, Harijadi, J. Fachiroh, D. K. Paramita, I. B. Tan, S. M. Haryana, and J. M. Middeldorp.2005. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and arcinoma-specific viral mRNA in relation to anti-EBV Immunoglobulin A (IgA) and IgG antibody level in blood of nasopharyngeal carcinoma.J. Clin. Microbiol. 43:3066-3073.
24. Stevens, S. J. C., S. A. W. M. Verkuijlen, M. C. Zwaan, and J. M. Middel-dorp. 2006. Epstein-Barr virus (EBV) serology, but not EBV DNA load, for predicting distant metastases in a juvenile Caucasian nasopharyngeal carcinoma (NPC) patient without clinical response upon EBV lytic induction therapy. Head Neck 28:1040-1045.
25. van Grunsven, W. M. J., A. Nabbe, and J. M. Middeldorp. 1993. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J. Med. Virol.40:161-169.
26. WHO International Agency for Cancer Research. 1997. Epstein-Barr virus, p. 47-373. IARC Monographs on the Evaluation of Carcinogenic Risks in Humans, publ. 70. IARC Press, Lyon, France.
27. Zeng, Y., C. H. Gong, M. G. Jan, Z. Fun, L. G. Zhang, and H. Y. Li. 1983.Detection of Epstein-Barr virus IgA/EA antibody for diagnosis of nasopha- ryngeal carcinoma by immunoautoradiography. Int. J. Cancer 31:599-601